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‘Persistent knowledge specialisation and intra-industry heterogeneity: 





This  paper  aims  to  contribute  to  the  analysis  of  within  industry  inter-firm  variety. 
Building  upon  the  knowledge-based  theory  of  the  firm  (Nelson  and  Winter,  1982; 
Penrose, 1959; Fransman, 1994), this paper develops two themes. First, the analysis of 
intra-industry heterogeneity: why do firms that operate in the same industry differ, and 
why are such differences persistent? Second, the paper investigates the extent to which 
higher performance is associated with the capacity of firms to expand their knowledge 
base (rather than with their initial conditions).  
 
Several authors (Patel and Pavitt, 1997, Granstrand et al., 1997) have pointed out that, 
even when large firms are increasingly technologically diversified, their technological 
competencies profiles are similar within industries while differing significantly between 
industries. At the same time, empirical evidence suggests that firms within the same 
industry display distinct strategic paths (Noda and Collis, 2001; McGee and Thomas, 
1986). These two streams of empirical evidence have led to the argument that there is 
not a one-to-one match between technological competence and product specialisation 
and that the dynamics of technological diversification are different from the dynamics 
of  downstream  diversification  (Gambardella  and  Torrisi,  1998).  This  paper  aims  to 
contribute  to  this  discussion,  providing  concrete  empirical  evidence  on  how  firms 
accumulate technological competencies and whether firms that manage to expand their 
knowledge bases are rewarded with indicators of better performance.  
 
The main contribution of the paper is empirical, based on a data source consisting of 
information  on  documents  published  in  scientific  international  journals  by  Spanish 
pharmaceutical  firms.  As  McMillan  and  Hamilton  (2000)  pointed  out,  the 
pharmaceutical industry is particularly appropriate for the employment of bibliometrics 
given that scientific research is critical to the development of new drugs. The Spanish 
pharmaceutical  industry provides the setting  for the study as an  industry  behind the 
technological frontier, where different levels of commitment to technological catching-  3
up  processes  by  firms  are  possible.  We  examine  the  extent  to  which  Spanish 
pharmaceutical  firms  are  building  capabilities  in  research,  and  about  the  kind  of 
capabilities being built. 
 
The paper is structured as follows. Section 2 reviews the literature and lays out the 
questions to be addressed. Section 3 describes the data sources. Section 4 identifies the 
two groups of firms we propose to analyse by describing their research and economic 
performance. Sections 5, 6 and 7 provide empirical evidence on different aspects of the 
knowledge  accumulation  process.  Section  8  discusses  the  relationship  between 
knowledge breadth and performance. Finally, Section 9 presents the conclusions.    
 
 
2.  Literature background 
 
The purpose of this paper is to study the factors that shape the scope and direction of 
firm' s technological capability accumulation and to examine the extent to which such 
factors  are  relevant  drivers  of  persistent  intra-industry  heterogeneity.  As  stated  by 
Cockburn  et al. (2000), there  is  no generally  accepted theory about the origins and 
dynamics  of  competitive  advantage:  some  scholars  stress  the  firm' s  external 
environmental  conditions  (Porter,  1980),  others  highlight  the  firm' s  endowments  of 
valuable, rare and difficult-to-imitate resources (Barney, 1991). By conceptualising the 
firm  as  a  learning  organisation,  focusing  on  the  ability  of  the  firm  to  develop  new 
capabilities, the knowledge-based theory of the firm provides a distinctive and fruitful 
framework within which to analyse how firms rebuild the industry structure to their 
advantage. In this sense, the knowledge-based theory of the firm provides an avenue for 
articulating  the  complementarities,  interconnections  between  Porter' s  external 
environments and Barney' s firm specific endowments, on a dynamic basis.   
 
2.1. Variety and stability of firms’ knowledge bases    
The knowledge-based theory of the firm aims to bring to the fore the argument that firm 
differences  matter.  Different  perceptions  and  understanding  of  the  economic 
environment may lead firms in the same line of business to employ different strategies. 
The  strategic  management  literature  has  provided  strong  evidence  of  the  variety  of 
strategies operating among firms within similar industries (McGee and Thomas, 1986).   4
However,  it  is  worth  noting  that  when  looking  at  the  technological  competencies 
accumulated by firms in the same industry, firms tend to display substantially similar 
profiles. Patel and Pavitt (1997) show that firms’ technological profiles (as measured by 
the distribution of patents across technical fields) are similar within industries while 
differing significantly between industries. In other words, firms competing in the same 
industry tend to accumulate similar technological competencies.   
 
This paper argues that the two above mentioned features are not in conflict: while firms 
need to accumulate a similar set of technological competencies to compete in a certain 
industry,  firms are  likely to ‘use’ such competencies  in different ways. Or, in other 
words, the firm’s knowledge base consists of something more than the distribution of 
patents (or publications) across technological fields; it also embraces how firms deploy 
such competencies to deliver new products. As Pavitt (1998) and Nelson (1998) argue, 
there  are  two  complementary  elements  in  firm-specific  knowledge:  bodies  of 
understanding (based on competencies in specific technological fields) and bodies of 
practice  (which  refers  to  the  organisational  knowledge  that  links  the  bodies  of 
understanding with the firm’s downstream, product specialisation). Dibiaggio and Nesta 
(2003) recently expanded this discussion by examining the empirical  foundations of 
these two concepts (studying the changing nature of the firms’ knowledge base in the 
context of biotech-related industries). Building upon the distinction between bodies of 
understanding and bodies of practice, this paper argues that intra-industry firm diversity 
should  be  analysed  appropriately  not  only  by  examining  the  firms’  technological 
competencies (bodies of understanding) or the firms’ product diversification strategies, 
but also by paying attention to the interface between the two. In this paper, we study this 
‘interface’  by  focusing  on  the  firms’  research  activities  examined  according  to  the 
products or processes that such activities are expected (by the firms) to originate and 
develop.
1  From  hereon,  we  refer  to this  ‘interface’  as  downstream-profiled  research 
activities. However inappropriate this terminology may be (and we admit that it is not 
very satisfactory), we do not conceive downstream-profiled research activities as being 
equivalent  to  applied  research;  on  the  contrary,  we  mean  by  this  term  to  embrace 
                                                 
1 Note that by focusing on the dowstream profile of the research activities we are only considering a small 
portion of what Pavitt (1998) and Nelson (1998) meant by ‘bodies of practice’. The downstream profile of 
research activites is just one of the many components of the firm’s organizational knowledge. 
Nevertheless, it is, we argue in this paper, a crucial component.    5
research  activities  that  are  very  exploratory  in  nature,  so  long  as  the  exploration  is 
conducted with a goal (expected materialisation) in mind.  
 
Moreover, as has been stressed by many authors (Stiglitz, 1987; Pavitt, 1987; Cantwell, 
1989; Antonelli, 1999), the process of firms’ learning is characterised by being a local 
process of knowledge acquisition: firms do not appear to scan all possible choices, but 
rather ‘they follow a specific course acting almost instinctively to capitalise on their past 
experience’  (Holbrook  et  al.,  2000:  1030).  In  this  sense,  the  evolution  of  firm' s 
knowledge  base  profiles  over  time  can  be  characterised  as  being  cumulative  and 
incremental and, thus, can be predicted to display a fairly stable pattern over time.   
 
In short, building upon the above discussion, we hypothesise that firms display stable 
patterns of specialisation (or diversification) in downstream-profiled research activities 
(that is, research activities evaluated according to the products or processes that they are 
expected to enable), and that such stable patterns of specialisation vary widely across 
firms.    
 
  2.2. Knowledge strategies and performance 
As several authors (Henderson and Cockburn, 1994; Powell et al, 1996) have noted, 
superior performance is associated with the firm' s capacity to create and accumulate 
knowledge  -  from  the  stock  of  patents  in  specific  disciplines  to  research  network 
particularities  and  other  forms  of  organisational  architectures  devoted  to  learning 
processes. In this sense, the management of knowledge becomes a crucial dimension for 
developing valuable, rare, difficult-to-imitate and non-substitutable resources: in other 
words,  a  source  of  competitive  advantage  (Leonard-Barton,  1995;  Bierly  and 
Chakrabarti, 1996).  
 
A degree of consensus has emerged among scholars as to what constitutes the crucial 
conflicting (but potentially reinforcing)  forces that knowledge  management needs to 
reconcile  or  balance  in  order  to  create  an  active  and  fruitful  learning  organisation 
(Argyris  and  Schön,  1978;  Leonard-Barton,  1995).  First,  as  argued  by  Cohen  and 
Levinthal (1989, 1990), March (1991) and Levinthal and March (1993), firms are likely 
to be rewarded in the long term with greater knowledge creation capabilities (and also 
with long term survival) the more they invest in in-house search activities and the more   6
exploratory the nature of the search, since such efforts contribute to strengthening the 
firm’s capacity to take advantage of knowledge generated outside its boundaries, and 
counterbalance the myopic features of experiential learning. However, such strategies 
generally involve higher levels of risk and costs than strategies guided by short-term 
optimisation of resources.  
 
Second, firms need not only to be competitive specialised players - in order to achieve 
world-class command within a certain discipline - but they also need to broaden their 
areas of expertise. This is so because broadening the knowledge base helps the firm, on 
the one hand, to be flexible in the face of technological change and on the other hand, to 
impose  causal  ambiguity  on  competitors  by  creating  knowledge  through  the 
combination  of  different  (but  familiar  to  the  firm)  technologies  or  bodies  of 
understanding (Leonard-Barton, 1995; Brusoni et al., 2001). However, as Pavitt (1998: 
440) points out, it is diversity downstream (in the product and process configurations 
that  can  be  generated  from  a  given  technological  knowledge)  rather  than  just 
technological diversity (which tends to be similar among firms within industries) that 
drives competition amongst innovating firms.  
 
Building  upon  the  above  discussion,  we  would  expect  that  better  performance  is 
strongly associated with the firm’s capacity to expand the scope of its areas of expertise 
in research activities. We also examine whether the firms’ diversity in technological 
competencies  and  firms’  diversity  in  downstream-profiled  research  activities  impact 
differently on performance.  
 
 
3.  Description of data sources and variables 
 
This  research  addresses  the  implications  for  empirical  analysis  of  the  propositions, 
discussed  in  Section  2,  drawing  upon  the  knowledge-based  theory  of  the  firm.  Our 
empirical analysis is designed to throw light on the characteristics of firms'  knowledge 
bases  and  on  their  implications  for  firms'   competitive  positions  and  innovative 
capabilities. To do this, we focus on the publication profiles of a set of active research 
players in an R&D intensive industry: the pharmaceutical industry. Publication counts 
are an important indicator of research activity in the pharmaceutical industry, as shown   7
by Koenig (1983), Narin and Rozek (1988), Gambardella (1995) and McMillan and 
Hamilton (2000) among others. Also, as noted by Cockburn et al. (2000), firms at the 
technological  frontier  have  increasingly  adopted  a  ‘science-driven  drug  discovery’ 
process: that is, firms not only tend to publish on average more over time, but they also 
tend to converge towards similar levels of publishing.   
 
The main objective in constructing the sample of pharmaceutical firms was to include 
every Spanish domestic firm active in research in order to have a sample of firms with a 
similar strategy. In other words, the aim was to work with an innovative group of firms 
seeking to accumulate capabilities oriented towards the generation and development of 
new products. 
 
We considered every domestic firm that had published at least one document in the 
period 1981-2000. The publication data were gathered from the Institute for Scientific 
Information' s (ISI) Science Citation Index (SCI) and the Web of Science. We collected 
data about every document published in the journals included in the ISI SCI in this 
period  for  which  at  least  one  author  address  was  that  of  a  Spanish  domestic 
pharmaceutical firm. 
 
This yielded a total of 1,210 published documents and a sample of 32 pharmaceutical 
firms (the list of firms is included in the Appendix) – accounting for approximately 28% 
of the total Spanish pharmaceutical market in 1999 in terms of sales. Most of these 
firms  were  founded  before  1955,  and  to  a  large  extent  they  have  continued  to  be 
domestic-owned since then; however, 11 out of the 32 firms had undergone changes in 
their ownership structure due to partial or total acquisition by multinational corporations 
(MNCs). Since most of these acquisitions only occurred in the eighties and nineties, and 
since author affiliations in all cases included domestic addresses, we included all 32 
firms in our research.
2 
 
                                                 
2 Moreover, from a random sample of 50 single authored articles (published since 1998), we confirmed 
that, with the exception of three cases, the authors were effectively affiliated to the firm (and not to a 
university or other publicly funded research centre). Therefore, we are confident about our assumption 
that authors are effectively affiliated to the firm. We are grateful to Dr F.Jimenez-Saez (INGENIO, 
Universidad Politecnica de Valencia, Spain) for his assistance in identifying authors’ affiliations.    8
We draw on publication data to build distinct measures capturing the different features 
of the firms’ knowledge base that we aim to study. First, to study trends in the firms’ in-
house research efforts we calculate the ratio of publications counts relative to firm size 
(in terms of total employees) on an annual basis. Second, to study the exploratory nature 
of the research we employ the concept of ‘‘research level’’ developed by CHI in order 
to classify journals on a continuum from the most applied to the most basic scientific 
research. As Narin and Rozek (1988) noted, in the context of biomedicine the four types 
of research are: clinical observation (Level 1), a mix of clinical observation and clinical 
investigation (Level 2), clinical investigation (Level 3) and basic research (Level 4).
3 
Given that most of the journals in the SCI database have been assigned to one of these 
levels, we can calculate the average research level for the publications of a given firm at 
any point in time. Finally, the profiles of firms’ knowledge bases are defined in terms of 
both  the  distribution  of  publications  across  scientific  sub-fields  and  the  therapeutic 
categories to which each publication belongs (see Sections 7 and 8 below). Sales data 
come from IMS Spain publications, employment and performance data are from Dun & 
Bradstreet and Sistema de Analisis de Balances Ibericos (SABI) publications. 
 
 
4.  The Spanish pharmaceutical industry: research and economic performance 
of Spanish pharmaceutical firms 
 
4.1. The regulatory environment 
We focus on the Spanish pharmaceutical industry to test the propositions derived from 
the knowledge-based theory of the firm. One of the interesting features of this industry 
case  is  that  the  regulatory  environment  has  not  been  characterised  historically  by 
specific  strategies  oriented  towards  innovation.  In  fact,  long-term  survival  in  the 
industry has not depended on research commitments for two main reasons. First, the 
lack of product patent protection until 1992 (Sequeira, 1998) and, thus, the existence of 
a regulatory environment that did not penalise imitation. Second, the Spanish national 
health system’s lax regulatory criteria for product introduction has favoured horizontal 
product  differentiation  strategies  and,  thus,  lowered  industry  entry  barriers  (Lobo, 
                                                 
3 As Narin and Rozek (1988) state, Level 1 is typified by the  Journal of the American Medical 
Association, Level 2, by the New England Journal of Medicine, Level 3, by the Journal of Clinical 
Investigation and Level 4, by the Journal of Biological Chemistry.   9
1992). Therefore, this study is examining the innovative patterns of a group of small and 
medium  sized  firms  (SMEs)  that  have  been  faced  with  a  less  than  encouraging 
innovation environment and which have followed a strategy mainly driven by purposive 
efforts towards rebuilding the industry structure in their favour.  
 
Indeed, as is shown in Section 4.3, a small set of Spanish domestic firms has been able 
to introduce world-class innovations (measured by new chemical compounds patented 
internationally). The focus of this research on firms that are reported to conduct research 
activities, allows us to investigate the extent to which research active players display 
similar  or  different  knowledge  management  strategies.  Firms  that  have  relied 
exclusively on other sets of capabilities (i.e. marketing and/or manufacturing) in order 
to survive in the industry are not considered.
4   
 
In this context, we wonder whether the knowledge base developed by the firms that 
have managed to obtain international patents (i.e. have innovated at world-class levels) 
is  significantly  different  from  those  of  other  Spanish  domestic  firms  conducting 
research activities.  
 
4.2. Research activity as captured by publications 
As mentioned above, Spanish domestic firms published 1,210 documents between 1981 
and  2000,  1,032  of  which  were  citable  (all  type  of  documents  excluding  Meeting 
Abstracts).
5 It is clear  from the evidence provided here that Spanish pharmaceutical 
firms  publish  much  more  than  they  patent.  Comparing  the  number  of  documents 
published by Spanish domestic pharmaceutical firms and the number of patents granted 
to Spanish domestic pharmaceutical  firms  by the US Patent Office (USPTO)  in the 
                                                 
4 Also, in order to have better control of the origins of the accmulated technological knowledge, we 
studied only domestic companies  to ensure that the research capabilities studied were effectively taking 
place in the firms analysed and not in foreign parent companies.  
5 This research provides evidence supporting the argument that the use of publications can be a good 
alternative to patents to address the innovative activities of firms in behind the technological frontier 
industries. In such industries firms have generally failed to achieve a critical mass of patents sufficient to 
allow for robust measures of innovative activities. Nevertheless, a caveat must be applied to the use of 
publications that the methodology may be applicable only to a very restricted group of industries, and 
particularly those generally classified as R&D intensive, where firms are forced to be well connected to 
the open science community in order to keep abreast with crucial technological advances. 
   10
period 1981-2000, publications clearly dominate (see Figure 1).
6 Moreover, not only is 
the number of publications always higher than the number of patents, but also the trend 
is  towards  continued  increase.  While  the  annual  average  number  of  documents 
published by Spanish domestic firms was 27 between 1981 and 1984, this rose to 108 in 
the period 1997-2000.      
 
{Insert Figure 1 about here} 
 
This increasing number of published documents is not just the product of an increasing 
number of firms publishing, or the result of less high quality research. Firms’ research 
efforts (as measured by number of publications per firm size), and the scientific value of 
these publications (as measured by the number of citations per document) have not been 
negligible.  When  compared  to  pharmaceutical  firms  at  the  technological  frontier, 
Spanish  firms  display  close  to  average  levels  of  citations  per  paper  and  levels  of 
research  efforts. Table  1  provides  figures  comparing  a  group of  US  pharmaceutical 
firms  with  some  of  the  Spanish  firms  most  actively  publishing.  It  can  be  seen  that 
generally  the  two  groups  of  firms  are  similar  in  most  respects  except  the  scale  of 
publications. In other words, according to the publications data, there is a set of Spanish 
domestic firms that perform relatively well in terms of quality of research and research 
productivity, when compared with firms at the frontier.   
 
{Insert Table 1 about here} 
 
4.3. Successful vs. ‘unsuccessful’ innovators  
While a relatively large number of firms have been active in research, as shown by the 
publications data, not all firms that publish have been equally successful in terms of 
technological performance (i.e. achieving international patents from active ingredients 
developed  in-house).  Indeed,  only  five  firms  can  claim  to  have  been  successful  in 
introducing new in-house chemical entities for which international patents have been 
granted and  for which  licences granted to MNCs. Table 2 summarises the group of 
Spanish firms that have successfully commercialised new products based on in-house 
                                                 
6 Patent data were gathered from the USPTO, the patents selected being those in which patent assignees 
were Spanish domestic firms, within the category ‘Drug, bio-affecting and body treating compositions’ 
(Class Numbers 424 and 514) from the US Patent Classification.      11
developed active ingredients. It should be noted that a large proportion of these in-house 
developed, internationally patented products have been economic successes, accounting 




We will refer to this group of firms as ‘innovative firms’, as opposed to the other firms 
that publish but that have not been successful in developing in-house active ingredients, 
which we will refer to as ‘non (successful) innovative’ firms.  This designation does not 
mean that this group of firms is not undertaking innovative activities; on the contrary, 
this latter group has obtained a large number of international patents over the period 
1981-2000,  but  for  new  methods,  processes  or  formulations  rather  than  new  active 
ingredients.  The  innovative  firms  group  comprises  five  firms;  the  non  (successful) 
innovative group accounts for the other 27 active research firms (as shown by their 
publication counts). 
 
{Insert Table 2 about here} 
 
  4.4. Economic performance 
Regarding economic performance, there are two issues to be noted. First, the group of 
innovative firms has been continuously growing since the mid-sixties, while the non-
innovative group has seen a persistent decrease in its aggregate market share (see Figure 
2).  Furthermore,  the  increasing  market  share  of  the  innovative  firms  is  even  more 
striking  when  compared  with  the  sharp  decrease  in  the  portion  of  the  total  market 
absorbed by all the other domestic firms. Second, the case of the innovative firms would 
seem to indicate that firm size is not a sufficient condition for success in innovating. 
None of the innovative firms were among the largest domestic firms in 1965. Indeed, in 
1965 Almirall was ranked 23rd in terms of sales including both domestic and foreign 
firms operating in Spain, with Esteve ranked 47th, Faes 20th, Ferrer 38th and Uriach 
37
th; while 6 domestic firms were among the largest 20 in the Spanish market by 1965 
(most of them belonging to our group of non-innovators). Also, Almirall, Esteve and 
Uriach  had  begun  research  activities  by  the  mid  to  late  sixties  -  as  stated  in  their 
company reports and confirmed by the fact that a large number of patents were granted 
                                                 
7 This is a significant percentage of firm’s total sales if we take into account that, as Schwartzman (1976) 
notes, the large majority of firms’ most important products account for between 15% and 20%.   12
to these firms in the seventies (see Table 2). In other words, while the five innovative 
firms rank among the largest domestic firms in the eighties and nineties, this was not the 
case in the mid sixties, and innovative success seem to have been either a causal factor 
of, or occurred simultaneously with, the process of growth experienced by these firms.    
 
{Insert Figure 2 about here} 
 
5. Basic trends in research efforts    
 
In this section we study the temporal profile of firms’ research activities and research 
efforts using the information on counts of published documents. As argued in Section 2, 
we would expect that a firm’s innovative success would be related to the firm’s in-house 
research efforts. Thus, it would be expected that the intensity of the research efforts of 
the group of innovative firms would be higher over time.  
 
When we compare firms’ research intensity over time (see Figure 3), the picture that 
comes out is that innovative firms, when comparing the 5 year moving averages, have 
higher levels of publications per hundred employees. However, these levels are only 
significant for five years when comparing the raw data on an annual basis.  
 
{Insert Figure 3 about here} 
 
Besides research intensity, it is also important to investigate whether these firms have 
been increasingly moving towards a higher degree of basic research activities: moving 
from  clinical  observation  towards  clinical  investigation  and  basic  research.  In 
accordance with the discussion in Section 2, we would expect that those firms that have 
been able to innovate – that is, to create new molecules - should show an increasing 
capability to command basic research. We examine this by classifying each publication 
in terms of type of research using the CHI research typology described in section 3, 
which  classifies  each  document  according  to  the  type  of  journal  in  which  it  was 
published. The four categories of research are: clinical observation (Level 1), a mix of 
clinical observation and clinical investigation (Level 2), clinical investigation (Level 3) 
and basic research (Level 4).  
   13
In  analysing  the  distribution  of  publications  over  time  across  the  different  types  of 
research,  the  non-innovative  firms  show  an  increasing  proportion  of  publications  in 
clinical observation (Levels 1 and 2) type of research, while the group of innovative 
firms  is  shown  to  have  increased  (by  10  percentage  points)  the  proportion  of 
publications in basic research (see Table 3).
8 
 
Thus, the innovative firms not only increased research intensity over the period 1981-
2000 (as shown in section 6.1) more than the non-innovative firms, but also it increased 
the proportion of publications in basic research (see Table 2), indicating that these firms 
had research capabilities that allowed them to conduct research of a more exploratory 
nature.  
 
{Insert Table 3 about here} 
 
6.  The breadth of firms’ knowledge bases  
 
As discussed in Section 2, in order to achieve world-class command within a certain 
discipline, firms need not only to be competitive specialised players, but they also need 
to  broaden  their  knowledge  base  (Leonard-Barton,  1995;  Patel  and  Pavitt,  1997; 
Brusoni et al., 2001). In this section we investigate whether firms have been broadening 
their knowledge base by studying two different dimensions of knowledge expertise. We 
look at the scope of the scientific bodies of knowledge that firms have  managed to 
integrate,  as  captured  by  the  number  of  scientific  disciplines  in  which  firms  have 
published.  This  can  be  interpreted  as the  firm’s  scientific  competencies  (for  similar 
interpretation and methodology for the pharmaceutical industry, see Narin and Rozek 
(1988)). We also investigate whether firms have expanded their knowledge expertise in 
terms of product-oriented research activities. Firms that are active in research in the 
pharmaceutical  industry  are  oriented  towards  the  discovery  and  development  of 
products that claim to be therapeutically  novel.  To achieve this goal,  firms  need to 
accumulate a certain level of experience in order to be effective in researching in a 
given  therapeutic  area  (Henderson  and  Cockburn,  1994).  Therefore,  we  look  at  the 
                                                 
8 It should be noted that the increasing proportion of documents classified in the category of clinical 
investigation is due to a large extent to the weight of three firms publishing extensively in scientific fields 
(i.e. allergy) in which clinical observation plays a disproportionate role.    14
scope of firms’ publications across therapeutic areas. We wonder whether there is a 
tendency for firms to be relatively specialised around a narrow set of therapeutic fields 
and also wonder about the stability of their specialisation. We also investigate the extent 
to which firms have managed to diversify their research portfolio across therapeutic 
areas and their capacity to conduct research on products intended to be active agents 
against various diseases.  
 
 
6.1.  Examining  the  firms’  knowledge  base:  diversification  of  scientific 
competencies  
This section, then, looks at whether firms have managed to integrate knowledge across a 
wide variety of scientific fields or have been accumulating scientific knowledge in only 
a narrow set of scientific fields. The CHI classification of journals in scientific fields 
(and sub-fields) is used in order to calculate the extent of diversification across scientific 
fields  of  firms’  published  documents.  It  can  be  seen  that  99%  of  the  documents 
published  by  the  Spanish  pharmaceutical  firms  belong  to  three  aggregate  scientific 
categories:  Clinical  Medicine  (including  scientific  sub-fields  such  as  Pharmacology, 
Pharmacy,  Cancer,  Cardiovascular  System,  Gastroenterology,  etc.),  Biomedical 
Research  (including  sub-fields  such  as  Biochemistry  &  Molecular  Biology, 
Microbiology, Biomedical Engineering, etc.) and Chemistry (i.e. Organic Chemistry, 
Analytical Chemistry, Physical Chemistry, etc.). This distribution profile of publications 
is  essentially  the  same  as  that  described  by  Narin  and  Rozek  (1988)  for  the  US 
pharmaceutical industry in 1976, where 86% of firms’ publications were classified in 
these  three  aggregated  scientific  categories  (although  the  firms  were  much  more 
diversified in terms of scientific sub-fields than those studied here). This similarity in 
the scope of scientific fields points to the fact that firms in the same industry need to 
accumulate  similar  ‘‘background’’  knowledge  in  order  to  become  active  research 
players (Patel and Pavitt, 1997). 
 
In order to compare the scientific knowledge diversification of  innovators and  non-
innovators  in  a  meaningful  way,  we  need  to  establish  a  minimum  number  of 
publications (some firms have too few to infer anything in terms of diversification). To 
do this, we compare the group of innovative firms with a sub-sample of 14 firms from 
the non-innovative group, which published at least 10 documents during 1981-2000.   15
These two groups differ significantly in terms of size (number of employees), the group 




Table  4  summarises  the  degree  of  diversification  of  documents  published  across 
scientific sub-fields by Spanish pharmaceutical firms in the period 1981-2000. It can be 
seen that the two groups of firms have very similar levels of diversification, either as 
measured by the Herfindahl Index (1 minus Herfindahl Index, to have a measure of 
diversification  instead  of  concentration)  or  as  measured  by  the  percentage  of 
publications  in  the  most  important  scientific  sub-fields.  Moreover,  even  when  the 
number of scientific sub-fields in which the firm has published at least one document is 
two times higher in the innovative group, the publication ratios of two groups do not 
significantly differ when the number of publications is normalised by the number of 
employees. 
 
{Insert Table 4 about here} 
 
According  to  Table  4,  we  would  reject  the  hypothesis  that  innovative  and  non-
innovative firms display different diversification levels of scientific competencies. Both 
types of firms have accumulated scientific expertise along a similar number of fields. 
There is no sign that innovative firms present a pattern of publications more evenly 
distributed across scientific fields, nor that they are actively publishing across a larger 
number of scientific fields (relative to their size). Moreover, consistent with Patel and 
Pavitt’s  (1997)  findings,  our  data  show  that  firms  competing  in  the  same  industry 
display  similar  knowledge  base  profiles.  As  will  be  shown  in  Section  7,  the  firms 
studied here have a distribution of publications across a similar spectrum of scientific 
sub-fields.    
 
 
6.2. Examining the firm’s knowledge base: diversification of downstream-
profiled research activities  
                                                 
9 These 14 firms are: Abello, Alter, Andromaco, Antibioticos, Cusi, Lacer, Lasa, Menarini-Puig, Vinas, 
Vita, ASAC, Leti, Grifols and Salvat. The average number of employees in these 14 firms at the end of   16
In this section we investigate whether firms have managed to diversify their knowledge 
base across therapeutic areas (i.e. cardiovascular system, respiratory system, etc.). As in 
the examination of scientific  fields, we  investigate whether  firms  have  been able to 
accumulate  knowledge  across  a  wide  variety  of  therapeutic  scientific  fields  or  have 
accumulated  knowledge  in  only  a  narrow  set  of  therapeutic  areas.  To  do  this  we 
classified the publications in terms of therapeutic fields (across the 15 therapeutic fields 
at  the  1  digit  level  of  the  Anatomical  Therapeutic  Classification  (ATC)).
10  The 
classification was carried out on the basis of the information contained in the keywords 
and abstracts provided by the ISI SCI database. Of the 1,032 citable documents (all 
documents excluding Meeting Abstracts), 12.8% were not classifiable into a therapeutic 
category because no clear indication could be obtained from the keywords or abstracts. 
In most cases, the papers that were not classified belonged to basic research (Level 4 of 
CHI  research  typology),  which  explains  why  no  particular  therapeutic  area  was 
indicated. This could be due to the exploratory nature of basic research and/or because 
the documents focused on the chemical characteristics of the molecule (rather than on 
its potential therapeutic effects). 
 
Table 5 provides figures on the diversification of firms’ publications across therapeutic 
categories comparing, as we did in Table 4, the firms in the innovative group with the 
14 largest firms from the non-innovative group. The patterns this time are significantly 
different. Innovative firms display a much higher degree of publication diversification 
across therapeutic fields.  
 
{Insert Table 5 about here} 
 
If we look at the profile of publications across therapeutic fields for these two groups of 
firms, it can be seen that the innovative firms display a broader spectrum of research 
expertise,  while  non-innovators  remain  narrowly  focused  throughout  the  period 
considered  (1981-2000)  (in  several  cases  one  therapeutic  area  accounts  for  all  the 
documents published by the firm).   
                                                                                                                                          
the nineties ranged between 80 and 1,900, while the average size for the five innovative firms was 
between 600 and 1,800. 
10 The 15 therapeutic areas are: Alimentary Tract and Metabolism (A), Blood and Blood Forming Organs 
(B), Cardiovascular System (C), Dermatologicals (D), Genito-Urinary System (G), Systemic Hormonal 
Preparations (H), General Anti-Inefctives (J), Cytostatics (L), Musculo-Skeletal System (M), Central   17
 
To sum up, analyses of the firms’ knowledge base diversification in terms of scientific 
knowledge  background  and  in  terms  of  research  pipeline  produced  very  different 
results. While both groups display a similar degree of diversification across scientific 
fields, they significantly differ in the degree of diversification of their research across 
therapeutic areas. Innovative firms have achieved a much broader knowledge base in 
terms of research across therapeutic fields than non-innovative firms.  
 
 
7. Variety and persistence of the firms’ knowledge base 
 
So, we can study the knowledge base of firms by looking at two different dimensions: 
the extent to which the firm has been able to expand its knowledge across scientific 
fields in order to conduct research activities and the extent to which the firm has been 
able to expand its research portfolio across therapeutic areas. In this section we focus 
not on the extent of diversification, but on the diversification profile in order to analyse 
both distinctiveness and stability of the knowledge base. 
 
It  has  been  shown  that  firms’  scientific  knowledge  bases  are  similarly  diversified 
between  innovative  and  non-innovative  firms.  We  now  want  to  test  whether  the 
composition of scientific fields in which firms are accumulating knowledge is similar or 
different  across  firms.  In  order  to  answer  this  question,  we  correlated  each  firm’s 
scientific knowledge profile (i.e. publication shares across scientific sub-fields) against 
those of all other firms . We consider all scientific sub-fields in which firms publish at 
least once over the period 1981-2000: this produces a total of 38 scientific sub-fields, 
84%  corresponding  to  Clinical  Medicine  and  Biomedical  Research  and  11%  to 
Chemistry  related  sub-fields  (the  remaining  5%  corresponding  to  Biology  and 
Agriculture & Food Science).
11 We find that the scientific knowledge profiles of these 
                                                                                                                                          
Nervous System (N), Parasitology (P), Respiratory System (R), Sensory Organs (S), Diagnostic Agents 
(T) and Various (V).   
11 The 38 scientific sub-fields are: General & Internal Medicine; Allergy; Cancer; Cardiovascular System; 
Dermatology; Endocrinology; Gastroenterology; Geriatrics; Hematology; Immunology; Obstetrics-&-
Gynecology; Neurology & Neurosurgery; Ophthalmology; Arthritis & Rheumatology; Pathology; 
Pharmacology; Pharmacy; Respiratory System; Nephrology; Veterinary; Hygiene & Public Health; Misc. 
Clinical Medicine;Physiology; Embryology; Genetics & Hereditary; Biochemistry & Molecular Biology; 
Cell Biology, Cytology, Histology; Microbiology; Virology; Biomedical Engineering; Microscopy;   18
firms  are  remarkably  similar,  as  indicated  by  the  fact  that  53%  of  the  cross-firm 
correlations  (90  out  of  171)  were  positive  and  significant  (see  Pearson  correlation 
coefficients in Table 6).
12 This evidence confirms that there are strong similarities in the 
scientific knowledge profile accumulated by firms in the same industry, regardless of 
whether or not they are successful innovators.  
 
{Insert Table 6 about here} 
 
These results are consistent with those of Patel and Pavitt (1997), which show that 
profiles of patent shares are more likely to be similar among firms belonging to the 
same industry than among firms belonging to different industries. However, here we are 
not comparing the firms’ knowledge profiles with those of non-pharmaceutical firms, 
but  we  provide  a  much  more  detailed  disaggregation  of  the  composition  of  firms’ 
knowledge profiles. In other words, the evidence here highlights that firms accumulate 
knowledge in similar scientific sub-fields (mainly within biomedicine) and firms have 
similar knowledge base composition in terms of the profile of scientific sub-fields in 
which they publish. This evidence points to the fact that pharmaceutical firms need to 
accumulate  a  similar  scientific  knowledge  background  in  order  to  become  active 
research  players;  or  in  other  words,  diversity  in  technological  (or  scientific) 
competencies can be interpreted as an entry barrier to competition in innovation.  
 
A completely different picture emerges when we address the firms’ research portfolio in 
terms of the distribution of publications across  therapeutic areas.  We correlate each 
firm’s publication shares across therapeutic areas against the other firms, based on the 
group  of  five  innovative  firms  and  the  top  14  from  the  non-innovative  group.  We 
consider all therapeutic areas (at the 1 digit level of the ATC) in which at least one 
document has been published by any of these firms in the period 1981-2000, which is 
all 15 categories. As Table 7 shows, each firm displays a distinct research portfolio. 
More  than  86%  of  total  possible  correlations  between  firms  were  not  significantly 
different from zero (at the 5% level of significance, using either Spearman or Pearson 
                                                                                                                                          
General Biomedical Research; Organic Chemistry; Analytical Chemistry; Physical Chemistry; General 
Chemistry; Biology; and Others.  
12 When Spearman rank-order correlation coefficients were used, 48% of correlations were positive and 
significant: see table in appendix.    19
correlation coefficients).
13 Therefore, the knowledge base varies to a large extent across 
firms in terms of their knowledge accumulation in research across therapeutic areas. In 
other words, variety across firms is largely confirmed by the firms’ research portfolios 
and thus supports the proposition that learning (knowledge creation) is a firm-specific, 
localised process. Firms deploy a common (though industry specific) set of scientific 
competencies along a variety of firm-specific research paths oriented to the generation 
and development of new products.  
 
{Insert Table 7 about here} 
Finally, we investigate whether the firm’s knowledge base is stable over time in order to 
assess the extent to which learning processes build upon prior experience and the extent 
to which the localised nature of learning imposes restrictions on shifts towards new, 
previously unexplored areas. Given that most of the non-innovative firms published in 
the nineties but not in the eighties, and given that they present a very narrow pattern of 
research diversification across therapeutic fields, we focus on the group of innovative 
firms in order to study firm’s knowledge base stability (see Table 8).  
 
We test whether stability in firms’ knowledge base is a significant phenomenon using 
the results derived from the correlations between the distributions of publications across 
therapeutic areas in different periods of time for each of the five innovative firms. The 
results, shown in Table 8, reject in all cases that the distribution of publications over 
time (for each firm) is random, highlighting that firms’ research across therapeutic areas 
does not change abruptly over time, which supports the proposition that cumulativeness 
is a major influence on firm’s research choices. 
 
{Insert Table 8 about here} 
 
8. Knowledge base diversification and performance 
 
We  conducted  some  regressions  to  examine  the  relationship  between  company 
performance  and  knowledge  base  diversification.  The  sample  is  composed  of  19 
Spanish pharmaceutical firms (the five innovative and 14 most active non-innovative) 
                                                 
13 Spearman rank-order correlation coefficients are shown in the appendix.   20
during the period 1995-2000. Three measures of performance were applied: (1) returns 
on sales (ROS); (2) returns on assets (ROA); and (3) the log of sales per employee 
(LN(SALES/L)).
14 We regressed each of these measures on three sets of variables. First, 
a  set of  variables  accounting  for  the  extent to which  the  companies  expanded  their 
knowledge base, both in terms of scope of technological (scientific) competencies and 
in terms of scope of downstream-profiled research activities, during the period 1995-
2000.  Second,  a  set  of  variables  accounting  for  the  ‘‘‘initial’’’  conditions  of  the 
company: age and size at the beginning of the period (1995). And third, a set of two 
variables accounting for firms’ investment efforts in physical assets (the stock of capital 
over employees during the period 1995-2000) and number of employees over the period 
1995-2000.  
    
To measure the first set of variables we have used the used the Herfindhal Index: more 
precisely, we  have computed ‘1 – Herfindhal Index’  in order to have a  measure of 
diversification on a year by year basis, over the firm’s distribution of publications, both 
across scientific fields and across therapeutic areas. Thus, we define THERAPSCOPEit 
as the ‘1-Herfindhal index’ computed on each firm’s distribution of publications across 
therapeutic categories for every year during 1995-2000. SCIENCESCOPEit is the ‘1 – 
Herfindhal index’ of the distribution of publications across scientific fields computed 
for every year and every company.
15 These two variables measure the extent to which 
the companies have expanded their knowledge base over the period 1995-2000. We use 
subscript ‘i’ to denote firms and ‘t’ to denote time.     
 
We also include a set of variables to assess the extent to which the firm displayed a 
highly diversified (or narrow) knowledge base at the beginning of the period considered. 
First, we computed the degree of knowledge diversification (1-Herfindhal index) for 
each firm, on the basis of its distribution of publications over the period 1981-1994. 
This  was  done  for  both  the  distribution  of  publications  across  therapeutic  areas 
(THSCOPE95i) and across scientific fields (SCISCOPE95i). We also explored another 
                                                 
14 Sales figures, after-tax profits and value of total assets were obtained from CD ROM SABI – see 
www.informasa.es.  
15 Note that for each single firm (and year) we have used data on firms’ publications for the four  
preceding  years, and then calculated a five year average. Therefore, the distribution of publications 
corresponding to the year 1995 includes both data on publications in that year and also data on firms’ 
publications in the four preceding years. This is done in order to make the best use of the information 
available and to obtain more meaningful trends for these variables.     21
way to capture the firm’s ‘accumulated’ knowledge breadth: an alternative regression 
includes LN(STOCKPUB)i, which accounts for the total amount of papers published by 
the  firm  between  1981  and  1994,  and  two  interaction  variables  that  assess  the 
‘combined’  effect  of  the  firm’s  stock  of  publications  with  THSCOPE95i  (called 
INTERACT1i) and with SCISCOPE95i (called INTERACT2i). 
 
The second set of variables attempts to control for the firm’s conditions pre-1995. In 
particular,  we  consider  the  firm’s  size  in  1995  (in  terms  of  the  log  of  number  of 
employees, LN(EMP95)i), and the age of the firm (AGEi) to assess whether firm size 
and earlier entry have a positive impact on performance. A positive impact of these two 
variables could be expected because of the greater internal financial resources available 
to larger firms and as a result of first-mover advantages gained by early entrants.    
 
Finally,  we  also  want  to  assess  whether  the  firm’s  commitment  to  investments  in 
physical  assets  is  strongly  associated  with  performance,  compared  with  the  firm’s 
efforts  towards  intangible  assets  (such  as  those  that  are  accounted  for  by 
THERAPSCOPEit and SCIENCESCOPEit). We take the stock of capital per employee, 
as capturing the firm’s capital intensity deepening (LN(K/L) it),
16 and the firm’s number 
of employees over time (LN(EMP)it).
17   
 
Thus, using a linear specification, our regressions are of the following form (where the 
dependent variable is one of our three measures of performance): 
 
PERFORMANCE it = CONST +  b1 THERAPSCOPE it +  b2 SCIENCESCOPE it +  
b3 (LN(EMP95))i + b4 AGEi +  b5 THSCOPE95 i + b6 SCISCOPE95i + b7  LN(K/L) it +  
b 8 LN(EMP)it + eit 
18 
 
                                                 
16 Stock of capital is measured by the firm’s value of annual ‘total assets’ , obtained from SABI. 
17 With the exception of variables accounting for firms’ knowledge diversification, all other variables 
have been computed using 3 year moving averages. So, for example, the values for firm employees in 
1995 is the average of the number of employees for the years 1994, 1995 and 1996.The same procedure 
was followed for the three performance measures.  
18 This is the expression for our first specification. The second specification includes the stock of 
publications and the two interaction effects (while removing the two variables accounting for the 
accumulated degree of firm’s knowledge base diversification up to 1995).   22
Table 9 presents the OLS estimates. One of the interesting outcomes displayed in Table 
9 is that the estimated coefficient of THERAPSCOPE is positive and significant in all 
regressions. This shows that there is a positive relationship between all performance 
measures  and  the  extent  to  which  firms  have  expanded  their  downstream-profiled 
research activities. Also, such positive relationship is not outweighed by the impact of 
firm size or firm’s capital intensity deepening and, thus, the strength of the relationship 
between THERAPSCOPE and performance has proved to be robust.  
 
The other  measure of  firm’s knowledge  breadth – the extent to which the  firm  has 
expanded  its  scientific  competencies  –  is  more  erratic  in  terms  of  its  degree  of 
association with performance. However, in terms of the two measures of profit ratios, 
the diversification of accumulated scientific competencies is shown by the interaction 
effect (INTERACT 2) to have a positive impact on performance. In other words, it is 
not just the actual stock of publications that matters; whether this stock of publications 
embraces more scientific fields is also significant. In fact, these results indicate that 
firms that have accumulated scientific competencies in only a very narrow set of fields 
have been penalised in terms of performance (see the negative sign of the estimated 
coefficient for the variable LN(STOCKPUB)). These results are consistent with those 
from  other  studies  (e.g.  Gambardella  and  Torrisi,  1998)  that  show  that  better 
performance  is  associated  with  companies  that  have  increased  their  technological 
diversification. 
 
{Insert Table 9 about here} 
 
One possible reason why the two variables accounting for firms’ knowledge breadth 
display a different profile when related to performance may be due to time-lag features. 
The outcomes from the regressions in Table 9 provide some preliminary evidence to 
support the  argument  that the  extent  to  which  firms  have  managed  to  expand  their 
scientific  competencies  has  a  positive,  but  deferred,  impact  on  performance  in 
comparison with firm’s capacity to expand its downstream-profiled research activities 
(which seem to have a more direct, concurrent) relationship with performance). In other 
words, the opportunities arising from technological (or scientific) diversification may 
take a long time to materialise and, therefore, the impact of technological diversification 
on performance can be assessed better by focusing on firms’ cumulative efforts.    23
 
There  is  one  instance  where  firm  scientific  diversification  (either  accumulated  or 
contemporaneous)  is  not  significantly  associated  with  performance.  This  is  the  case 
when performance is measured in terms of the log of sales per employees when the 
firm’s  capital  intensity  deepening  may  outweigh  the  long-term  impact  of  variables 
related to technological diversification. Nevertheless, even in this specification, there is 
a significant and positive association between the firm’s increasing diversification in 
downward-profiled research activities and performance.  
 
Finally, it is important to note that such variables as initial size or age have very little or 
no impact on performance. This lends further support to the argument that purposive 
management (and particularly management of firms’ intangible assets) is important in 
explaining  performance:  better  performance  does  not  emerge  straightforwardly  from 
earlier entry or larger size: deliberate efforts towards innovation  must be made.Also, 
the  fact  that  the  estimated  coefficient  linked  to  the  firms’  efforts  towards  physical 
investments (stock of capital per  employees) always  shows a  highly  significant and 
positive  association  with  performance,  indicating  that  commitments  towards 
accumulation of physical assets and broadening knowledge are complementary rather 
than  substitutive.  In  other  words,  commitments  in  these  two  directions  may  be  self 
reinforcing when assessed in terms of impact on innovative capacity and performance.     
  
 
9. Summary and conclusions 
 
There have been two themes running through this paper: intra-industry firm variety, and 
the  relationship  between  the  knowledge  base  and  performance  of  the  firm.  The 
empirical results from this study support the following conclusions: 
 
1.  To get a better understanding of the interfaces between firms’ technological 
competencies and product diversification, particular attention should be paid 
to  downstream-profiled  research  activities.  As  the  empirical  evidence 
presented here shows, while firms competing in the same industry tend to 
accumulate competencies across a similar set of scientific fields, they display 
significantly  different  patterns  in  terms  of  the  downstream  (or  product-  24
oriented)  profile  of  research  activities  (here  downstream-profiled  research 
activities were studied by examining the distribution profile of publications 
across therapeutic areas).  
 
Moreover, these  differences  persist  over time:  firms  do  not  suddenly  change 
their  direction  of  research,  but  remain  firmly  committed  to  certain  research 
paths, with gradual changes occurring over time. In short, both variety between 
firms and persistency in firms’ differences within an industry owe much to the 
distinction  between  ‘products’  and  ‘technologies’,  and  to  the  firm-specific 
organisational knowledge that allows a given set of technologies to be deployed 
in different ways.   
 
2.  Better performance is positively associated with the capacity of firms to expand 
their  knowledge  breadth,  as  measured  both  in  terms  of  diversification  of 
technological competencies and diversification of downstream-profiled research 
activities. However, the (positive) association with performance is much more 
consistent across different performance measures in the case of diversification of 
downstream-profiled  research  activities  than  in  the  case  of  diversification  of 
scientific  competencies  (as  measured  by  the  degree  of  diversification  of 
publications across scientific fields). This result is consistent with the argument 
in this paper that while technological competencies are essentially the necessary 
ticket  of  entry  to  competition  in  industry,  it  is  how  those  technological 
competencies  are  organised  to  produce  new  products  and  processes  that  will 
potentially  generate  a  distinctive  capability  and,  eventually,  may  result  in 
sustainable competitive advantage.  
 
In summary, the empirical results support the argument that the firm’s knowledge base 
is a main driver of persistent heterogeneity within industries on the one hand, because of 
the  systematic  variety  in  terms  of  how  firms  articulate  and  organise  their  research 
activities  and  their  background  knowledge,  and  on  the  other  hand,  because  of  the 
positive correlation between the firms’ knowledge diversification and performance.  
 
The fact that an industry behind the technological frontier was chosen for this analysis 
adds  an  additional  dimension.  This  research  provides  evidence  on  the  knowledge   25
accumulation processes of technological followers in an R&D intensive industry. The 
extent to which these firms will be able to catch-up technologically with those at the 
frontier remains to be seen, but the evidence provided in this research shows that some 
firms  have  performed  very  well  in  terms  of  generating  world-class  innovations  and 
acquiring research capabilities. The evidence shows that the successful innovative firms 
have been strongly committed to research activities for a long period of time and that 
these research activities are becoming increasingly explorative. Moreover, successful 
innovative  firms  have  broadened  their  knowledge  base  (as  measured  by  the 
accumulation  of  knowledge  across  therapeutic  areas)  to  a  greater  extent  than  the 
(unsuccessful)  innovative  firms.  Lastly,  the  evidence  presented  here  shows  that  the 
deliberate, purposive efforts towards R&D investment are the basis of a virtuous circle - 
the relationship between market success and innovation.  
 
This study has two limitations that would be promising future avenues of research. First, 
the time length in this study is probably too short to properly analyse the direction of 
causality  between  performance  (i.e.  growth,  market  success  or  profit  ratios)  and 
innovative capacity (or the breadth of the firm’s knowledge base): longer time series 
would be necessary to consider time lags and causality. However, this study does show 
that initial size does not, in isolation, have a significant impact on future performance or 
the capacity to innovate. Moreover, building upon the evidence presented here, it can be 
argued that there  is  a  reinforcing  relationship  between  the  broadening  of  the  firm’s 
knowledge base and better performance.  
 
Second, firms’ organisational knowledge should be studied in more depth. Investigating 
more  qualitative  aspects  of  the  firm’s  knowledge  architecture  would  add  to  our 
understanding  of  the  interfaces  between  technological  capabilities  and  downstream 
strategies. Examining what we call here the downstream-profile of research activities 
has proved worthwhile, but should be complemented with other elements of the firm’s 
internal organisation of research activities.    26
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Appendix: List of Spanish firms 
Laboratorios Abello SA 
Laboratorios ASAC 
Aldo Union, SA 
Almirall-Prodesfarma 
Laboratorios Alter SA 
Laboratorios Andromaco SA 
Laboratorios Alonga SA 
Antibioticos SA 
Laboratorios Aristegui 
Industrial Farmaceutica Cantabria SA 
Cepa 
Laboratorios Cinfa SA 
Laboratorios Cusi SA 
Laboratorios Esteve, SA 
Faes 
Ferrer Internacional SA 
Laboratorios Grifols SA 
Juste SA Quimico Farmaceutica 
Laboratorios Lacer SA 
Lasa 
Laboratorios Leti SA 
Llorente 
Menarini (Puig) 
Laboratorios Normon SA 
Laboratorios Rubio SA 
Seid SA 
Laboratorios SALVAT 
J.Uriach & Cia 
Laboratorios Vinas SA 
Laboratorios Vita SA 
Laboratorios Dr Andreu 
Laboratorios ELMU   30
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Table A. Correlations of firms’ publication shares across 38 scientific sub-fields (1981-2000) 
  Esteve  Ferrer  Uriach  Faes  Abello  Andro.  Alter  Antib.  Cusi  Lacer  Lasa  Menar.  Vinas  Vita  ASAC  Leti  Grifols  Salvat 
Almir.  0.486**  0.416**  0.340*  0.346*  0.514**  0.275*  0.363*  0.102  0.299*  0.233  0.344*  0.311*  0.057  0.125  0.240  0.328*  0.158  0.516** 
Esteve    0.564**  0.391**  0.664**  0.533**  0.451**  0.454**  0.022  0.270  0.315*  0.516**  0.509**  0.278*  0.320*  0.223  -0.031  -0.011  0.316* 
Ferrer      0.357*  0.457**  0.244  0.149  0.427**  0.054  0.188  0.374*  0.501**  0.573**  -0.100  0.271  -0.017  0.002  0.062  0.304* 
Uriach        0.348*  0.332*  0.198  0.546**  0.479**  0.202  0401**  0.371*  0.595**  0.027  0.497**  0.321*  0.104  0.055  0.271 
Faes          0.414**  0.346*  0.636**  0.042  0.091  0.357*  0.559**  0.692**  0.013  0.365*  0.078  -0.146  -0.001  0.175 
Abello            0.252  0.374*  0.103  0.159  0.218  0.246  0.426**  0.080  0.021  0.365*  0.370*  -0.036  0.246 
Andro.              0.186  0.021  0.067  0.396*  0.206  0.063  0.354*  0.381**  0.289*  0.164  0.022  -0.032 
Alter                0.207  0.270  0.721**  0.481**  0.620**  -0.009  0.326*  0.258  -0.039  0.402**  0.353* 
Antib.                  0.394*  0.295*  0.282*  0.207  0.091  0.515**  0.380**  0.100  -0.133  0.295* 
Cusi                    0.352*  0.138  0.270  0.138  0.260  0.441**  0.157  -0.117  0.553** 
Lacer                      0.313*  0.352*  0.060  0.483**  0.339*  0.075  0.399**  0.261 
Lasa                        0.521**  0.065  0.471**  0.124  -0.087  -0.148  0.217 
Menar.                          -0.009  0.326*  0.258  0.074  -0.189  0.358* 
Vinas                            0.191  0.334*  0.094  -0.148  0.264 
Vita                              0.243  0.039  -0.100  0.154 
ASAC                                0.363*  -0.177  0.343* 
Leti                                  -0.203  0.226 
Grifols                                    -0.148 
Notes: * p < 0.05; ** p < 0.01 (one tailed). Spearman rank-order correlation coefficients. 
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Table B. Correlations of firms’ publication shares across 15 therapeutic categories (1 digit ATC; 1981-2000) 
  Esteve  Ferrer  Uriach  Faes  Abello  Andro.  Alter  Antib.  Cusi  Lacer  Lasa  Menar.  Vinas  Vita  ASAC  Leti  Grifols  Salvat 
Almir.  0.383  0.230  0.152  0.881**  -0.011  0.039  0.410  0.152  -0.507*  0.184  0.443*  0.161  0.287  0.315  0.193  -0.346  -0.138  0.338 
Esteve    0.201  0.326  0.403  0.048  -0.286  0.161  0.193  -0.074  -0.160  -0.056  0.357  0.161  0.000  0.245  -0.315  0.012  0.005 
Ferrer      0.515*  0.245  -0.247  0.078  0.022  0.023  -0.153  -0.025  0.401  0.081  0.369  0.457*  0.371  -0.261  0.175  0.213 
Uriach        0.048  0.007  -0.076  0.485*  0.084  -0.160  0.515*  0.172  0.293  -0.135  -0.262  0.502*  -0.262  0.403  -0.267 
Faes          0.025  0.132  0.420  0.116  -0.307  0.123  0.375  0.250  0.360  0.489*  0.090  -0.210  -0.307  0.417 
Abello            0.337  0.254  0.331  -0.270  0.032  -0.410  0.003  -0.342  -0.184  0.342  0.516*  0.032  -0.410 
Andro.              0.090  0.603**  -0.310  0.048  0.371  -0.343  -0.071  0.247  0.411  0.424  0.362  0.175 
Alter                0.118  -0.233  0.640**  0.000  0.490*  0.000  -0.159  0.312  -0.159  0.233  -0.071 
Antib.                  -0.195  -0.195  0.026  -0.066  -0.247  -0.133  0.310  -0.133  0.320  0.003 
Cusi                    -0.153  -0.232  -0.271  -0.194  -0.105  -0.270  -0.105  -0.153  -0.233 
Lacer                      0.263  0.058  -0.194  -0.105  0.191  -0.105  0.500*  -0.233 
Lasa                        -0.411  0.039  0.318  0.408  -0.159  0.263  0.233 
Menar.                          0.350  -0.185  -0.213  -0.185  -0.271  0.238 
Vinas                            0.619**  -0.343  -0.133  -0.194  0.878** 
Vita                              -0.185  -0.071  -0.105  0.557* 
ASAC                                0.258  0.494*  -0.411 
Leti                                  -0.105  -0.159 
Grifols                                    -0.233 
Notes: * p < 0.05; ** p < 0.01 (one tailed). Spearman rank-order correlation coefficients.   32
Figure 1. 





































































































Note: Documents published include citable  documents (Meeting abstracts are excluded). Patent data are from 























Abbott Labs  12.6  0.4  1,968  Almirall-Prodesfarma  12.7  0.4  72 
American Home Products  8.2  0.2  1,215  Alter  9.9  0.2  19 
Bristol-Myers Squibb   10.1  0.5  3,386  Andromaco  13.7  0.4  20 
Johnson & Johnson  17.5  0.2  2,482  Antibioticos  9.8  0.1  13 
Eli Lilly & Co.  12.6  0.9  3,488  Esteve  9  0.4  53 
Merck & Co.  18.6  1.4  6,135  Faes  4.3  0.3  11 
Pfizer Inc.  9.4  0.4  2,030  Ferrer  5.4  0.5  70 
Schering-Plough  11.9  0.5  1,321  Lasa  9  0.5  15 
Upjohn  12.9  1.4  3,602  Uriach  5.7  0.5  33 
Warner-Lambert Co.  8.4  0.3  1,605  Viñas  12.1  0.7  21 
Mean  12.2  0.6  2,723  Mean  9.2  0.4  33 
Notes: 1. Comparisons on publications refer to citable documents. 2. Figures on US firms are author’s own 
calculations  from  data  on  publications  provided  in  McMillan  and  Hamilton  (2000)  and  data  on  firms’ 
employees from Fortunes (various years). US firm data refer to the firm’s US units only. Don’t you need the 
US names more fully out or explained – we can shorten the column titles – again we talk about this – but I am 
trying to think ahead for the book   33
 
Table  2.  List  of  successfully  commercialised  and  internationally  patented  in-house 
developed active ingredients 
Firm  In-house developed 
active ingredients 
Date of international patent  Therapeutic area 
Almirall*
  Clebopride  Germany 1975: US 1979  Antiemetic/Antispasmodic 
  Almagate  Belgium 1979: US 1984  Antacid 
  Piketoprofen  UK 1976  Anti-inflammatory (topic) 
  Cinitrapide  Germany 1979: US 1991  Gastroprokinetic 
  Ebastine  US 1985  Antihistaminic 
  Almotriptan  US 1996  Anti-migraine 
Esteve  Suxibuzone  Germany 1970: US 1973  Anti-inflammatory 
  Dobesilate  France 1968: US 1970  Vasotropic 
  Sultosilate  Netherlands Patent. 1973: US 1976  Antihyperlipoproteinemic 
Faes  Dosmalfate  US 1993  Anti-ulcer 
Ferrer  Ebrotidine  US 1988  Anti-ulcer 
  Dotarizine  US 1989  Anti-migraine 
  Sertaconazole  US 1992  Anti-fungal 
Uriach  Fosfosal  Germany 1978  Analgesic/Anti-inflammatory 
  Trifusal  Germany 1977: US 1978  Anti-thrombotic 
  Flutrimazole  US 1992  Anti-fungal 
* The table does not include the patents granted to Prodesfarma before its merger with Almirall in 1997.  





































1. Mergers and acquisitions were addressed by restating the separate companies as a single entity for the 
period prior to the merger or acquisition.  
2. In 1965 two firms (out of 27) from the non-innovators had not yet been founded.  
3.  The  figures  for  total  domestic  firms  include  all  domestic,  including  non-innovators  but  excluding 
innovators.  
4. The remaining market share (up to 100%) corresponds to MNCs operating in Spain.    
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Figure 3.  
















































































Table 3 Percentages of publications by research type 














1981-2000           
Innovative  5 %  12 %  62 %  21 %  528 
Non-innovative  11 %  23 %  47 %  19 %  447 
1981-1990           
Innovative  9 %  7 %  70 %  14 %  133 
Non-innovative  2 %  16 %  59 %  22 %  140 
1991-2000           
Innovative  4 %  13 %  59 %  24 %  395 
Non-innovative  15 %  27 %  41 %  17 %  307 
Note:  The  total  number  of  publications  reported  in  the  table  is  lower  than  the  total  citable  documents 
published (i.e. all documents except Meeting Abstracts) by these firms because 5.5% of the documents were 
published in journals that were not included in the CHI list.   35
 
Table 4. Diversification across scientific sub-fields (1981-2000) 
  1 – Herfindahl 
Index 
C1 (% of publications 
accounted for by the 
largest sub-field) 
No. sub-fields with 





Innovators  0.64  57  13  1.7 
Non-Innovators
1  0.66  48  6  2.9 
t-Test
2  Not Significant  Not Significant  Significant  Not significant 
Notes:  
1.The group of non-innovators includes only the subset of 14 (largest publishing) firms.  
2. t-Test for equality of means (2-tailed, 5% significance level). Non-parametric tests (i.e. Mann-Whitney 




Table 5. Diversification across therapeutic categories (1981-2000) 
  1 – Herfindahl 
Index 
C1 (% of publications 
accounted for by largest 
therapeutic area) 
No. therapeutic 





Innovators  0.77  33  8.6  1.8 
Non-Innovators
1  0.29  79  3.4  1.1 
t-Test
2  Significant  Significant  Significant  Not significant 
Notes: 
1.The group of non-innovators includes only the subset of 14 (largest publishing) firms.  
2. t-Test for equality of means (2-tailed, 5 % significance level). Non-parametric tests (i.e. Mann-Whitney 
test), testing differences in average ranks for the two groups, yielded similar results.  
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Table 6. Correlations of firms’ publication shares across 38 scientific sub-fields (period 1981-2000) 
  Esteve  Ferrer  Uriach  Faes  Abello  Andro.  Alter  Antib.  Cusi  Lacer  Lasa  Menar.  Vinas  Vita  ASAC  Leti  Grifols  Salvat 
Almir.  0.961**  0.964**  0.944**  0.857**  0.029  0.219  0.908**  0.501**  0.916**  0.145  0.698**  0.945**  0.743**  0.933**  0.576**  0.045  -0.041  0.188 
Esteve    0.978**  0.966**  0.921**  -0.015  0.218  0.952**  0.499**  0.891**  0.155  0.724**  0.993**  0.755**  0.940**  0.580**  -0.012  -0.068  0.187 
Ferrer      0.977**  0.883**  -0.039  0.234  0.944**  0.514**  0.911**  0.200  0.746**  0.980**  0.762**  0.965**  0.590**  -0.021  -0.056  0.165 
Uriach        0.868**  -0.032  0.251  0.950**  0.604**  0.914**  0.214  0.745**  0.977**  0.765**  0.980**  0.604**  -0.003  -0.062  0.219 
Faes          -0.035  0.254  0.889**  0.407**  0.771**  0.242  0.756**  0.924**  0.638**  0.855**  0.491**  -0.066  -0.081  0.131 
Abello            0.212  -0.036  -0.061  -0.045  -0.065  -0.050  -0.022  -0.016  -0.041  -0.004  0.931**  -0.074  -0.016 
Andro.              0.220  0.041  0.179  0.547**  0.566**  0.213  0.270  0.303*  0.186  0.413**  -0.055  -0.055 
Alter                0.533**  0.873**  0.325*  0.724**  0.964**  0.712**  0.920**  0.570**  -0.037  0.131  0.277* 
Antib.                  0.548**  0.112  0.378**  0.530**  0.379**  0.606**  0.349*  -0.056  -0.112  0.385** 
Cusi                    0.161  0.650**  0.895**  0.716**  0.904**  0.575**  -0.019  -0.080  0.269 
Lacer                      0.677**  0.180  0.077  0.277*  0.084  -0.077  0.360*  0.127 
Lasa                        0.734**  0.539**  0.798**  0.416**  -0.050  -0.090  0.080 
Menar.                          0.748**  0.946**  0.588**  -0.019  -0.079  0.235 
Vinas                            0.771**  0.477**  0.043  -0.104  0.310* 
Vita                              0.598**  -0.010  -0.065  0.143 
ASAC                                0.044  -0.085  0.159 
Leti                                  -0.099  -0.032 
Grifols                                    -0.101 
Notes: * p < 0.05; ** p < 0.01 (one tailed). Pearson correlation coefficients. 
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Table 7. Correlations of firms’ publication shares across 15 therapeutic categories (1 digit ATC; period 1981-2000) 
  Esteve  Ferrer  Uriach  Faes  Abello  Andro.  Alter  Antib.  Cusi  Lacer  Lasa  Menar.  Vinas  Vita  ASAC  Leti  Grifols  Salvat 
Almir.  0.536*  0.479*  -0.058  0.793**  -0.188  -0.203  0.347  -0.165  -0.218  -0.058  0.458*  0.129  0.372  0.363  0.439  -0.196  -0.239  0.361 
Esteve    0.289  -0.101  0.177  -0.217  -0.299  0.067  0.360  -0.206  -0.215  0.590*  0.258  -0.078  -0.108  0.566*  -0.218  -0.056  -0.099 
Ferrer      0.142  0.579*  -0.164  -0.199  -0.012  -0.151  -0.157  -0.140  0.465*  -0.153  0.555*  0.551*  0.320  -0.157  -0.153  0.559* 
Uriach        -0.139  -0.162  -0.174  0.305  -0.054  -0.171  0.840**  0.236  -0.153  -0.174  -0.164  0.483*  -0.164  0.785**  -0.178 
Faes          -0.153  -0.093  0.191  -0.148  -0.173  -0.089  0.179  0.010  0.842**  0.846**  0.104  -0.156  -0.210  0.839** 
Abello            0.379  -0.062  -0.076  -0.086  -0.092  -0.122  -0.089  -0.092  -0.077  0.039  0.999**  -0.099  -0.097 
Andro.              -0.072  0.022  -0.133  -0.077  0.019  -0.139  -0.071  -0.048  -0.089  0.383  -0.065  -0.015 
Alter                -0.016  -0.101  0.028  -0.104  -0.01  -0.100  -0.091  0.400  -0.091  -0.015  -0.107 
Antib.                  -0.093  -0.103  -0.117  -0.096  -0.100  -0.084  0.050  -0.084  0.323  -0.100 
Cusi                    -0.098  -0.126  -0.094  -0.095  -0.080  -0.173  -0.080  -0.107  -0.100 
Lacer                      0.233  -0.095  -0.105  -0.088  0.338  -0.088  0.879**  -0.111 
Lasa                        -0.133  -0.041  -0.019  0.802**  -0.113  0.204  -0.036 
Menar.                          0.056  -0.084  -0.165  -0.084  -0.113  0.033 
Vinas                            0.989**  -0.186  -0.085  -0.115  -0.998** 
Vita                              -0.156  -0.071  -0.096  0.990** 
ASAC                                0.031  0.373  -0.196 
Leti                                  -0.096  -0.090 
Grifols                                    -0.121 
Notes: * p < 0.05; ** p < 0.01 (one tailed). Pearson correlation coefficients. 
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Table 8. Analysis of persistence in research across 15 therapeutic categories: Spearman 
rank-order correlation coefficients   


















***  ---  --- 
Notes: ***, p < 0.01; **, p < 0.05; * p < 0.1 (one tailed). First column compares the periods 1991-1995 
and 1996-2000; second column compares the periods 1986-90 and 1996-2000; third column compares the 
periods 1981-1990 and 1991-2000. For each firm the total number of publications were as follows: 
Almirall-Prodesfarma, 185;  Ferrer, 130; Esteve, 89; Uriach, 70; Faes, 28. Faes has most of its 
publications in the nineties and thus only the sub-periods 1991-1995 and 1996-2000 could be compared.   39
Table 9. Relationship between knowledge base diversification and performance 
  Measures of performance 
  Returns on sales  Returns on assets  Ln(Sales/Employees) 
















































































---  0.059 
(0.05) 
---  -0.392 
(0.248) 
--- 
SCISCOPE95  0.005 
(0.024) 
---  0.042 
(0.028) 









































---  0.042 
(0.075) 
INTERACT1  ---  0.025
** 
(0.012) 
---  0.021 
(0.014) 
---  -0.085 
(0.072) 






---  -0.021 
(0.078) 
No. of observations  114  114  114  114  114  114 
R
2  0.53  0.54  0.42  0.45  0.48  0.47 
Adjusted R
2  0.49  0.50  0.38  0.40  0.44  0.43 
Notes: * P < 0.1; ** P < 0.05: *** P < 0.01. Standard errors in parenthesis.  
The 114 observations correspond to our 19 firms over the period 1995-2000.  
 